Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148


Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.

Davis MB, Vasquez-Dunddel D, Fu J, Albesiano E, Pardoll D, Kim YJ.

Clin Cancer Res. 2011 Jun 15;17(12):3984-92. doi: 10.1158/1078-0432.CCR-10-3262. Epub 2011 May 4.


A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Xiao L, Kim J, Lim M, Dai B, Yang L, Reed SG, Baltimore D, Wang P.

Vaccine. 2012 Mar 28;30(15):2570-81. doi: 10.1016/j.vaccine.2012.01.074. Epub 2012 Feb 5.


Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.

Jung ID, Jeong SK, Lee CM, Noh KT, Heo DR, Shin YK, Yun CH, Koh WJ, Akira S, Whang J, Kim HJ, Park WS, Shin SJ, Park YM.

Cancer Res. 2011 Apr 15;71(8):2858-70. doi: 10.1158/0008-5472.CAN-10-3487. Epub 2011 Mar 2.


The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.

Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.

Int J Oncol. 2006 Apr;28(4):947-53.


Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.

Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S.

Clin Cancer Res. 2004 Apr 15;10(8):2891-901.


TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells.

Narusawa M, Inoue H, Sakamoto C, Matsumura Y, Takahashi A, Inoue T, Watanabe A, Miyamoto S, Miura Y, Hijikata Y, Tanaka Y, Inoue M, Takayama K, Okazaki T, Hasegawa M, Nakanishi Y, Tani K.

Cancer Immunol Res. 2014 Jun;2(6):568-80. doi: 10.1158/2326-6066.CIR-13-0143. Epub 2014 Apr 10.


Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.

Nakamura M, Iwahashi M, Nakamori M, Ueda K, Ojima T, Naka T, Ishida K, Yamaue H.

Oncology. 2005;68(2-3):163-70. Epub 2005 Jul 4.


Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.

Ohshio Y, Teramoto K, Hanaoka J, Tezuka N, Itoh Y, Asai T, Daigo Y, Ogasawara K.

Cancer Sci. 2015 Feb;106(2):134-42. doi: 10.1111/cas.12584. Epub 2015 Jan 16.


Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ.

J Exp Med. 1996 Jan 1;183(1):87-97.


The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.

Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, Miller JF, Liau LM.

J Immunol. 2006 Jan 1;176(1):157-64.


Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines.

Ali OA, Doherty E, Mooney DJ, Emerich D.

Biomatter. 2011 Jul-Sep;1(1):66-75. doi: 10.4161/biom.1.1.16277.


Rhamnogalacturonan II is a Toll-like receptor 4 agonist that inhibits tumor growth by activating dendritic cell-mediated CD8+ T cells.

Park SN, Noh KT, Jeong YI, Jung ID, Kang HK, Cha GS, Lee SJ, Seo JK, Kang DH, Hwang TH, Lee EK, Kwon B, Park YM.

Exp Mol Med. 2013 Feb 8;45:e8. doi: 10.1038/emm.2013.14.


[Inhibiting effect of IL-10 in tumor microenvironment on anti-tumor activity of SOCS1-silenced DC vaccine].

Wang Z, You H, Song S.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Apr;29(4):379-83. Chinese.


Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

Furumoto K, Soares L, Engleman EG, Merad M.

J Clin Invest. 2004 Mar;113(5):774-83.


Campylobacter jejuni-induced activation of dendritic cells involves cooperative signaling through Toll-like receptor 4 (TLR4)-MyD88 and TLR4-TRIF axes.

Rathinam VA, Appledorn DM, Hoag KA, Amalfitano A, Mansfield LS.

Infect Immun. 2009 Jun;77(6):2499-507. doi: 10.1128/IAI.01562-08. Epub 2009 Mar 30.


Adjuvant effect of lipopolysaccharide on the induction of contact hypersensitivity to haptens in mice.

Yokoi S, Niizeki H, Iida H, Asada H, Miyagawa S.

J Dermatol Sci. 2009 Feb;53(2):120-8. doi: 10.1016/j.jdermsci.2008.08.009. Epub 2008 Sep 30.


Improved efficacy of dendritic cell-based immunotherapy by cutaneous laser illumination.

Chen X, Zeng Q, Wu MX.

Clin Cancer Res. 2012 Apr 15;18(8):2240-9. doi: 10.1158/1078-0432.CCR-11-2654. Epub 2012 Mar 5.


Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.

Ali OA, Verbeke C, Johnson C, Sands RW, Lewin SA, White D, Doherty E, Dranoff G, Mooney DJ.

Cancer Res. 2014 Mar 15;74(6):1670-81. doi: 10.1158/0008-5472.CAN-13-0777. Epub 2014 Jan 30.


Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.

Okamoto M, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M.

Cancer Res. 2004 Aug 1;64(15):5461-70.


IFNβ produced by TLR4-activated tumor cells is involved in improving the antitumoral immune response.

Núñez NG, Andreani V, Crespo MI, Nocera DA, Breser ML, Morón G, Dejager L, Libert C, Rivero V, Maccioni M.

Cancer Res. 2012 Feb 1;72(3):592-603. doi: 10.1158/0008-5472.CAN-11-0534. Epub 2011 Dec 2.

Supplemental Content

Support Center